Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Philipp Bewersdorf

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Best Practice & Research. Clinical Haematology|December 6, 2020
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?Jan Philipp Bewersdorf, Amer M Zeidan
Leukemia & Lymphoma|May 19, 2020
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?Jan Philipp Bewersdorf, Amer M Zeidan
Cells|October 21, 2020
Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?Jan Philipp Bewersdorf, Amer M Zeidan
Annals of Hematology|February 21, 2020
Evolving therapies for lower-risk myelodysplastic syndromesJan Philipp Bewersdorf, Amer M Zeidan
Expert Review of Hematology|October 20, 2020
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new eraJan Philipp Bewersdorf, Amer M Zeidan
Med (New York, N.Y.)|June 14, 2025
More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trialTed M Getz, Jan Philipp Bewersdorf
Hematology. American Society of Hematology. Education Program|December 9, 2022
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging conceptsJan Philipp Bewersdorf, Raajit K Rampal
Best Practice & Research. Clinical Haematology|March 25, 2021
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?Jan Philipp Bewersdorf, Amer M Zeidan
Expert Review of Hematology|September 3, 2020
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Jan Philipp Bewersdorf, Amer M Zeidan
Leukemia|April 10, 2019
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromesJan Philipp Bewersdorf, Amer M Zeidan
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Best Practice & Research. Clinical Haematology|December 6, 2020
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?Jan Philipp Bewersdorf, Amer M Zeidan
Leukemia & Lymphoma|May 19, 2020
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?Jan Philipp Bewersdorf, Amer M Zeidan
Cells|October 21, 2020
Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?Jan Philipp Bewersdorf, Amer M Zeidan
Annals of Hematology|February 21, 2020
Evolving therapies for lower-risk myelodysplastic syndromesJan Philipp Bewersdorf, Amer M Zeidan
Expert Review of Hematology|October 20, 2020
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new eraJan Philipp Bewersdorf, Amer M Zeidan
Med (New York, N.Y.)|June 14, 2025
More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trialTed M Getz, Jan Philipp Bewersdorf
Hematology. American Society of Hematology. Education Program|December 9, 2022
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging conceptsJan Philipp Bewersdorf, Raajit K Rampal
Best Practice & Research. Clinical Haematology|March 25, 2021
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?Jan Philipp Bewersdorf, Amer M Zeidan
Expert Review of Hematology|September 3, 2020
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Jan Philipp Bewersdorf, Amer M Zeidan
Leukemia|April 10, 2019
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromesJan Philipp Bewersdorf, Amer M Zeidan
Pageof 11